Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Relations between study investigators, advisors, and sponsors

Neurology

Volumn 48, Issue 3, 1997, Pages 572-574

  Lublin, Fred D ^a   Reingold, Stephen C ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b National Multiple Sclerosis Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NEW DRUG; PLACEBO;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0030979128     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.3.572     Document Type: Review

References (10)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, placebo-controlled trial. Neurology 1993;43:655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
4. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
5. Reingold SC. The new partnership in multiple sclerosis: relations with industry. Multiple Sclerosis 1995;1:141-142.
6. Subcommittee on Motor Neuron Diseases of The World Federation of Neurology Research Group on Neuromuscular Disease et al. Airlie house guidelines: therapeutic trials in amyotrophic lateral sclerosis. J Neurol Sci 1995;129(suppl):1-10.
7. Whitaker JN. Expanded clinical trials of treatments for multiple sclerosis. Ann Neurol 1993;34:755-756.
8. Barnett HJM, Sackett DL. Monitoring clinical trials. Neurology 1993;43:2437-2438.
9. Armstrong PW, Furberg CD. Clinical monitoring boards: the search for a constitution. Circulation 1994;91:901-904.
10. Spilker B. Guide to clinical trials. New York: Raven Press, 1991.